Related Experiment Video
Updated: Jan 10, 2026

Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices
Published on: November 29, 2024
Construction of Gastrodin Nanocarriers and Their Improving Effect on Gastric Ulcers
Yanfei Li1,2,3, Qiong Shen4, Lixia Yang1,2,3
1Pharmacy College, Guizhou University of Traditional Chinese Medicine, Guiyang 550025, China.
Abstract:
In the pathogenesis of gastric ulcer, mitochondrial dysfunction can exacerbate oxidative stress levels. Gastrodin (Gas), a key active component in food-drug homologous platycodon grandiflorum extract, exhibits significant anti-inflammatory and antioxidant properties. However, the complex gastrointestinal environment can pose limitations on the oral administration of free Gas, as is the case with many drugs. This study aimed to develop a mitochondrially functionalized (5-carboxypentyl) (triphenyl) phosphonium bromide (TPP) Gas nanoparticle system to effectively prevent ethanol-induced gastric ulcers in mice. Gas nanoparticles (Gas-NPs) were successfully synthesized through enzymatic reaction, followed by the synthesis of TPP mitochondrial-targeted functionalized Gas nanoparticles system (GT-NPs) through amide reaction. In vitro experiments demonstrated the efficient uptake of GT-NPs by human gastric epithelial cells (GES-1) with precise mitochondrial targeting and excellent antioxidant capabilities. Furthermore, GT-NPs exhibited gradual disintegration and release in simulated gastric fluid (SGF), effectively reducing oxidative stress, cell apoptosis, inflammatory infiltration, and the expression levels of PCNA and BAX proteins in gastric tissues of mice with ethanol-induced gastric ulcers. Collectively, our findings suggest that GT-NPs hold promise as targeted oral controlled release agents for the treatment of gastric ulcers.
Related Concept Videos
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Peptic Ulcer Disease IV: Management
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
Bioavailability Enhancement: Drug Stability Enhancement and GI Retention
Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors
Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...

